Loading…

Design and synthesis of pyrazole derivatives against neutrophilic inflammation

Neutrophils are the most abundant immune cells. However, neutrophil dysregulation leads to acute and chronic inflammation and is involved in various diseases. The aim of this study was to develop anti-inflammatory agents in human neutrophils. A drug screening was conducted on in-house compounds with...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2023-12, Vol.262, p.115874-115874, Article 115874
Main Authors: Yu, Ko-Hua, Tien, Kai-wen, Wang, Wei-Chun, Chi, Ching-Ho, Tsai, Keng-Chang, Chou, Chen-Hsi, Hwang, Tsong-Long, Hung, Hsin-Yi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neutrophils are the most abundant immune cells. However, neutrophil dysregulation leads to acute and chronic inflammation and is involved in various diseases. The aim of this study was to develop anti-inflammatory agents in human neutrophils. A drug screening was conducted on in-house compounds with the potential to inhibit the respiratory burst, which involves the generation of superoxide anions in human neutrophils. Bioisosteric replacement was then applied to design more active derivatives. The most potent inhibitors of superoxide anion generation activity were compounds 58 and 59, which had IC50 values of 13.30 and 9.06 nM, respectively. The inhibitory effects of 58 and 59 were reversed by H89, a PKA inhibitor. PDE selective screening indicated that the best inhibitory effects were PDE4B1 and PDE4D2, and the inhibitory activities were 83% and 85%, respectively, at a 10 μM concentration of 59. The final molecular simulation experiment highlighted the slightly different binding poses of 58 and 59 in the PDE4 active site. An in vivo pharmacokinetic study revealed that the half-life of 59 was approximately 79 min when using intravenous bolus administration. This work introduced a new class structure of PDE4 inhibitors resulting in potent neutrophil inactivation activity, with the aim of contributing to new anti-inflammatory drug discovery. [Display omitted] •The most potent inhibitor of ROS was 59 with IC50 values of 9.06 nM.•The inhibitory effect of 59 was reversed by H89, a PKA inhibitor.•The best inhibitory effects were PDE4B1 and PDE4D2.•Docking highlighted the binding poses of 59 in the PDE4 active site.•An in vivo pk study revealed that the half-life of 59 was approximately 79 min.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2023.115874